Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Pm 01183
2. Pm-01183
3. Pm01183
1. 497871-47-3
2. Pm01183
3. Tryptamicidin
4. Zepzelca
5. Pm-01183
6. Pm-1183
7. 2cn60tn6zs
8. Pm 01183
9. Pm1183
10. [(1r,2r,3r,11s,12s,14r,26r)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] Acetate
11. Zepsyre
12. Lurbinectedin [inn]
13. Unii-2cn60tn6zs
14. Lurbinectedin [mi]
15. Lurbinectedin [usan:inn]
16. Lurbinectedin [usan]
17. Lurbinectedin [who-dd]
18. Chembl4297516
19. Schembl16152477
20. Gtpl10681
21. Dtxsid30198065
22. Lurbinectedin [orange Book]
23. Ex-a4316
24. Who 9397
25. Nsc826275
26. S9603
27. At22223
28. Cs-6323
29. Db12674
30. Nsc-826275
31. Hy-16293
32. J3.531.659k
33. J3.652.626b
34. Pm01183;pm-1183;ly-01017;ryptamicidin
35. Q27254568
36. (1'r,6r,6ar,7r,13s,14s,16r)-8,14-dihydroxy-6',9-dimethoxy-4,10,23-trimethyl-19-oxo-2',3',4',6,7,9',12,13,14,16-decahydro-6ahspiro(7,13-azano-6,16-(epithiopropanooxymethano)(1,3)dioxolo(7,8)isoquinolino(3,2-b)(3)benzazocine-20,1'-pyrido(3,4-b)indol)-5-yl Acetate
37. [(1r,2r,3r,11s,12s,14r,26r)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22
38. Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12h-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocine-20,1'-(1h)pyrido(3,4-b)indol)-19-one, 5-(acetyloxy)-2',3',4',6,6a,7,9',13,14,16-decahydro-8,14-dihydroxy-6',9-dimethoxy-4,10,23-trimethyl-, (1'r,6r,6ar,7r,13s,14s,16r)-
Molecular Weight | 784.9 g/mol |
---|---|
Molecular Formula | C41H44N4O10S |
XLogP3 | 3.9 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 4 |
Exact Mass | 784.27781479 g/mol |
Monoisotopic Mass | 784.27781479 g/mol |
Topological Polar Surface Area | 190 Ų |
Heavy Atom Count | 56 |
Formal Charge | 0 |
Complexity | 1530 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 7 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Lurbinectedin is indicated for the treatment of adult patients with metastatic small-cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Treatment of small cell lung cancer
Lurbinectedin exerts its chemotherapeutic activity by covalently binding to DNA, resulting in double-strand DNA breaks and subsequent cell death. Lurbinectedin has been associated with myelosuppression, and patients receiving therapy with this agent should be closely monitored for evidence of cytopenias. Prior to beginning therapy, ensure baseline neutrophil counts are >1,500 cells/mm3 and platelet counts are >100,000/mm3. The supplementary use of granulocyte colony-stimulating factor (G-CSF) should be considered if the neutrophil count falls below 500 cells/mm3. Lurbinectedin has also been associated with hepatotoxicity. Monitor liver function tests at baseline and regular intervals throughout therapy, and consider holding, reducing, or permanently discontinuing therapy based on the severity of observed hepatotoxicity.
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XX - Other antineoplastic agents
L01XX69 - Lurbinectedin
Absorption
Following intravenous administration, the Cmax and AUC0-inf were 107 g/L and 551 g*h/L, respectively. No accumulation between dosing intervals (every 3 weeks) has been observed. No significant differences in absorption were found between special populations (e.g. based on age, sex, ethnicity, etc.), but lurbinectedin has not been studied in the setting of severe renal impairment or moderate/severe hepatic impairment.
Route of Elimination
Approximately 89% of a given dose is recovered in the feces (<0.2% unchanged) and 6% in the urine (1% unchanged).
Volume of Distribution
The steady-state volume of distribution of lurbinectedin is 504 L.
Clearance
The total plasma clearance of lurbinectedin is approximately 11 L/h.
Lurbinectedin is metabolized primarily by CYP3A4 _in vitro_, though specific data regarding its biotransformation are lacking. An N-desmethylated metabolite has been identified in canine subjects.
The terminal half-life of lurbinectedin is 51 hours.
Lurbinectedin is a DNA alkylating agent. It covalently binds to guanine residues in the DNA minor groove, forming adducts that bend the DNA helix towards the major groove. This process triggers a cascade of events that affect the activity of transcription factors and impairs DNA repair pathways, ultimately leading to double-strand DNA breaks and eventual cell death. Additional mechanism(s) of action include inhibition of RNA-polymerase-II activity, inactivation of Ewing Sarcoma Oncoprotein (EWS-FL11) via nuclear redistribution, and the inhibition of human monocyte activity and macrophage infiltration into tumor tissue.
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Lurbinectedin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lurbinectedin, including repackagers and relabelers. The FDA regulates Lurbinectedin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lurbinectedin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lurbinectedin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lurbinectedin supplier is an individual or a company that provides Lurbinectedin active pharmaceutical ingredient (API) or Lurbinectedin finished formulations upon request. The Lurbinectedin suppliers may include Lurbinectedin API manufacturers, exporters, distributors and traders.
click here to find a list of Lurbinectedin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lurbinectedin DMF (Drug Master File) is a document detailing the whole manufacturing process of Lurbinectedin active pharmaceutical ingredient (API) in detail. Different forms of Lurbinectedin DMFs exist exist since differing nations have different regulations, such as Lurbinectedin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lurbinectedin DMF submitted to regulatory agencies in the US is known as a USDMF. Lurbinectedin USDMF includes data on Lurbinectedin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lurbinectedin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lurbinectedin suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lurbinectedin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lurbinectedin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lurbinectedin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lurbinectedin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lurbinectedin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lurbinectedin suppliers with NDC on PharmaCompass.
Lurbinectedin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lurbinectedin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lurbinectedin GMP manufacturer or Lurbinectedin GMP API supplier for your needs.
A Lurbinectedin CoA (Certificate of Analysis) is a formal document that attests to Lurbinectedin's compliance with Lurbinectedin specifications and serves as a tool for batch-level quality control.
Lurbinectedin CoA mostly includes findings from lab analyses of a specific batch. For each Lurbinectedin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lurbinectedin may be tested according to a variety of international standards, such as European Pharmacopoeia (Lurbinectedin EP), Lurbinectedin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lurbinectedin USP).
LOOKING FOR A SUPPLIER?